- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00315354
Popular Diets Study
22 de novembro de 2016 atualizado por: David S. Ludwig, MD, PhD, Boston Children's Hospital
Popular Diets, Metabolism, and CVD Risk
The aim of this study is to evaluate the effects of three dominant dietary patterns - conventional low-fat, low-glycemic index (GI) and very-low-carbohydrate - on energy metabolism and heart disease risk factors following weight loss in obese young adults in a feeding study
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
For most of the last half century, reduction in fat intake has been the primary nutritional approach for the prevention and treatment of obesity and cardiovascular disease (CVD).
Over the last few years, very low carbohydrate (Atkins-type) diets have achieved great popularity, with publication of several studies suggesting greater weight loss and improvements in CVD risk factors over 3 to 6 months.
Recently, a third dietary approach focused on glycemic index (GI) has generated interest.
However, few studies have compared the effects of these diets on body weight regulation and risk for CVD.
The primary hypotheses of this study are that any diet that lowers the postprandial rise in blood glucose (very-low-carbohydrate or low-GI) will have beneficial effects on the physiological adaptations to weight loss and on some CVD risk factors.
However, other CVD risk factors will be adversely affected by a very-low-carbohydrate vs. a low-GI diet.
Preliminary data provide strong support for these hypotheses, by showing that resting energy expenditure declines less and CVD risk factors improve more with weight loss on a low-glycemic load diet compared to a conventional low-fat diet.
This application proposes a cross-over feeding design to study the effects of three diets following 12.5% weight loss in obese young adult subjects (n = 24, age 18 to 40 years).
The diets are: 1) conventional low-fat, with 60% carb, 20% fat, 20% protein; 2) low-GI with 40% carb, 40% fat, 20% protein; and 3) very-low-carbohydrate with 10% carb, 60% fat, 30% protein.
The primary outcome is resting energy expenditure (indirect calorimetry).
Secondary outcomes include total energy expenditure (doubly labeled water), thermic effect of food (indirect calorimetry), physical activity (accelerometry), insulin resistance and B-cell function (frequently-sampled OGTT), blood lipids, blood pressure and measures of systemic inflammation and coagulopathy.
This study should have major public health implications to the millions of Americans currently following diets to decrease body weight and risk for heart disease.
Tipo de estudo
Intervencional
Inscrição (Real)
24
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Children's Hospital Boston
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 40 anos (Adulto)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- BMI ≥ 27 kg/m2
- Willing and able to come to the GCRC 5 days per week to consume a supervised meal and pick-up food for all other meals
- Available for scheduled hospital admissions
- Willing to abstain from alcohol consumption for the duration of the study
- If female, regular menstrual cycles (defined as 26 to 30 days between cycles; no more than one day variation in the duration of menstrual flow)
Exclusion Criteria:
- Weight > 350 lbs
- Change in body weight (± 10%) over preceding year
- Taking any medications or dietary supplements that might affect body weight, appetite, or energy expenditure
- Smoking (1 cigarette in the last week)
- High levels of physical activity
- Currently following a special diet
- Abnormal laboratory screening tests
- Type 2 diabetes mellitus
- Allergies or aversions to foods on the study menu
- Previous diagnosis of an eating disorder or any other mental health disorder
- If female, pregnant in the past 12 months or planning to become pregnant during the study period
- If female, lactating in the preceding 12 months
- If taking birth control medication, change in medication in previous 3 months or plans to change medication during the study period
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: 2
Dieta com baixo teor de gordura
|
Feeding protocol, all foods prepared in a metabolic kitchen
|
|
Experimental: 1
Low glycemic index diet
|
Feeding protocol, all foods prepared in a metabolic kitchen
|
|
Comparador Ativo: 3
Very low carbohydrate diet
|
Feeding protocol, all foods prepared in a metabolic kitchen
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
resting energy expenditure using indirect calorimetry in the fasting state
Prazo: end of each dietary period
|
end of each dietary period
|
|
insulin resistance assessed by frequently-sampled oral glucose tolerance test
Prazo: end of each dietary period
|
end of each dietary period
|
|
thyroid function tests
Prazo: end of each dietary period
|
end of each dietary period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
total energy expenditure using doubly labeled water methodology
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
thermic effect of food using indirect calorimetry
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
physical activity using accelerometry
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
serum lipids
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
plasminogen activator inhibitor-1
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
C-reactive protein
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
blood pressure
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
hunger/appetite
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
insulin 30 minutes after oral glucose (as an effect modifier)
Prazo: baseline
|
baseline
|
|
|
Core temperature
Prazo: End of each dietary period
|
End of each dietary period
|
|
|
secreted frizzle-related protein-4
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
heme-oxygenase
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
Irisin
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
fibroblast growth factor-21
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
chemerin
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
trimethylamine N-oxide
Prazo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
alanine aminotransferase
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
Uric acid
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
insulin
Prazo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
ghrelin
Prazo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
gastric inhibitory peptide
Prazo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
GLP1
Prazo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
PYY
Prazo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
Amylin
Prazo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
Leptin
Prazo: end of each dietary period
|
end of each dietary period
|
|
|
Metabolomic analysis
Prazo: end of each dietary period
|
Evaluate the effect of diet on metabolomic profile in plasma, with the aim of assessing dietary adherence and exploring diet-disease mechanisms
|
end of each dietary period
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Cara B Ebbeling, PhD, Boston Children's Hospital
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Walsh CO, Ebbeling CB, Swain JF, Markowitz RL, Feldman HA, Ludwig DS. Effects of diet composition on postprandial energy availability during weight loss maintenance. PLoS One. 2013;8(3):e58172. doi: 10.1371/journal.pone.0058172. Epub 2013 Mar 6.
- Ebbeling CB, Swain JF, Feldman HA, Wong WW, Hachey DL, Garcia-Lago E, Ludwig DS. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA. 2012 Jun 27;307(24):2627-34. doi: 10.1001/jama.2012.6607.
- Hron BM, Ebbeling CB, Feldman HA, Ludwig DS. Hepatic, adipocyte, enteric and pancreatic hormones: response to dietary macronutrient composition and relationship with metabolism. Nutr Metab (Lond). 2017 Jul 5;14:44. doi: 10.1186/s12986-017-0198-y. eCollection 2017.
- Esko T, Hirschhorn JN, Feldman HA, Hsu YH, Deik AA, Clish CB, Ebbeling CB, Ludwig DS. Metabolomic profiles as reliable biomarkers of dietary composition. Am J Clin Nutr. 2017 Mar;105(3):547-554. doi: 10.3945/ajcn.116.144428. Epub 2017 Jan 11. Erratum In: Am J Clin Nutr. 2022 Feb 9;115(2):601.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de abril de 2006
Conclusão Primária (Real)
1 de junho de 2010
Conclusão do estudo (Real)
1 de abril de 2013
Datas de inscrição no estudo
Enviado pela primeira vez
14 de abril de 2006
Enviado pela primeira vez que atendeu aos critérios de CQ
14 de abril de 2006
Primeira postagem (Estimativa)
18 de abril de 2006
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
23 de novembro de 2016
Última atualização enviada que atendeu aos critérios de controle de qualidade
22 de novembro de 2016
Última verificação
1 de novembro de 2016
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1R01DK072428 (Concessão/Contrato do NIH dos EUA)
- R01DK072428 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .